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Arnold J. Levine negatively regulated by the adenovirus E1B-55Kd pro-
tein and the human MDM2 protein. In both cases, p53Department of Molecular Biology
amino acid residues 22 and 23 play a key role in theLewis Thomas Laboratory
binding of p53 to E1B-55Kd or MDM2 (Lin et al., 1995).Princeton University
Thus, the negative regulators of p53-mediated transcrip-Princeton, New Jersey 08544
tion target some of the same p53 amino acids critical
to positive regulation of transcriptional activation.
These results clearly point out that p53 uses a hy-The p53 gene and its protein product have become the
drophobic interface in its N-terminal domain to interactcenter of intensive study ever since it became clear
with the transcriptional machinery of the cell and itsthat slightly more than 50% of human cancers contain
negative regulators. Recently, the N-terminal domain ofmutations in this gene. An extensive database (Hollstein
MDM2 was cocrystalized with a peptide containing p53et al., 1994) catalogs these mutations in more than 50
amino acid residues 13–29, covering the portion of p53different cell and tissue types, although some types of
that was shown, by mutational analysis, to interact withcancers never appear to select for p53 mutations (Lutz-
MDM2. The MDM2 domain forms a deep hydrophobicker and Levine, 1996). The nature of these genetic
pocket, and the p53 peptide forms an amphipathic helixchanges in cancer cells is most commonly a missense
with its hydrophobic surface, pointing into and fillingmutation in one allele, producing a faulty protein that is
the hydrophobic pocket. F19, W23, and L26 all stabilizethen observed at high concentrations in these cells,
these hydrophobic interactions in this pocket betweenfollowed by a reduction to homozygosity. More rarely,
p53 and MDM2 (Kussie et al., 1996).deletions or chain-termination mutations in the p53 gene
The sequence-specific DNA-binding domain of p53 isindicate that the null phenotype predisposes to cancer,
localized between amino acid residues 102 and 292. It isas has been observed in mice with a homozygous p53
a protease-resistant and independently folded domainnull mutation (Donehower et al., 1992). There have been
containing a Zn21 ion that is required for its sequence-some suggestions that the missense mutant producing
specific DNA-binding activity. This domain folds into aa faulty p53 protein could contribute a “gain of function”
four-stranded and five-stranded antiparallel b sheet thatphenotype (Dittmer et al., 1993), but this remains to be
in turn is a scaffold for two a-helical loops that interact
substantiated by additional experimentation.
directly with the DNA (Cho et al., 1994). The tetrameric
A study of the mutational spectra at the p53 locus in
p53 protein (which is a dimer of a dimer) binds to four
different tissue types indicates a strong role for diverse
repeats of a consensus DNA sequence 59-PuPuPuC(A/
environmental mutagens, with a set of tissue prefer-
T)-39, and this sequence is repeated in two pairs, each
ences. In addition, there is strong selection for a subset
arranged as inverted repeats such as →←→←, where
of mutations localized predominantly in the DNA-bind- → is the sequence given above. Residues K120, S241,
ing domain of the protein. Several codons in this domain
R273, A276, and R283 make contacts with the phos-
that are never observed in the p53 mutational spectra
phate backbone in the major groove, while K120, C277,
have been altered by site-specific mutagenesis, and in
and R280 interact via hydrogen bonds to the DNA bases.
all cases these mutations have no phenotype and be-
R248 then makes multiple hydrogen bond contacts in
have like the wild-type (Lin et al., 1995). Thus, both the minor groove of the DNA helix (Cho et al., 1994).
selection and a strong set of environmental mutagens More than 90% of the missense mutations in p53 reside
combine to produce mutations in the p53 gene in human in this sequence-specific DNA-binding domain, and
cancers. these mutations fall into two classes. Mutations in amino
acid residues such as R248 and R273, the two most
p53 Domains: Structure–Function Relationships frequently altered residues in the protein, result in defec-
The p53 protein is a transcription factor that enhances tive contacts with the DNA and loss of the ability of p53
the rate of transcription of six or seven known genes that to act as a transcription factor. A second class of p53
carry out, at least in part, the p53-dependent functions in mutations disrupts the structural basis of the b sheet
a cell (Table 1). The human p53 protein contains 393 and the loop–sheet helix motif that acts as a scaffold in
amino acids and has been divided structurally and func- this domain. These structural mutations alter the confor-
tionally into four domains. The first 42 amino acids at mation of the p53 protein and produce a protein that now
the N-terminus constitute a transcriptional activation reacts with the monoclonal antibody PAb240, whose
domain that interacts with the basal transcriptional ma- epitope (residues 212–217) is not accessible to the bind-
chinery in positively regulating gene expression. Amino ing of this antibody in the native or wild-type structure.
acids 13–23 in the p53 protein are identical in a number More than 40% of the missense mutations are localized
of diverse species. The p53 amino acids F19, L22, and to residues R175, G245, R248, R249, R273, and R282,
W23 have been shown to be required for transcriptional which play a role in the structural integrity of this domain
activation by the protein in vivo (Lin et al., 1995). These or the DNA contact sites directly (Cho et al., 1994;
same amino acids make contacts with and bind to (in Hollstein et al., 1994).
vitro) the TATA-associated factors TAFII70 and TAFII31, The native p53 protein is a tetramer in solution, and
both of which are subunits of TFIID (Lu and Levine, amino acid residues 324–355 are required for this oligo-
merization of the protein. The structure of this domain1995; Thut et al., 1995). p53 transcriptional activation is
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but some evidence has suggested that ubiquitin-medi-Table 1. Products of Genes Transcriptionally Activated by p53
ated proteolysis plays a role. In addition to this low
p21, WAF1, Cip1 Inhibits several cyclin–cyclin-dependent
protein concentration, in some cells p53 probably alsokinases; bind cdk’s, cyclins, and PCNA; arrest
exists in a latent form, inactive for transcription. Underthe cell cycle
these conditions, the p53 protein must receive a signalMDM2 Product of an oncogene; inactivates p53-medi-
ated transcription and so forms an autoregula- or alteration to activate it to function. The upstream
tory loop with p53 activity events or signals that flow to p53 are mediated by sev-
GADD45 Induced upon DNA damage; binds to PCNA and eral stressful situations. Several different types of DNA
can arrest the cell cycle; involved directly in
damage can activate p53, including double-strandDNA nucleotide excision repair
breaks in DNA produced by g-irradiation and the pres-Cyclin G A novel cyclin (it does not cycle with cell divi-
ence of DNA repair intermediates afterultraviolet irradia-sion) of unknown function and no known cyclin-
dependent kinase tion or chemical damage to DNA. This results in a rapid
Bax A member of the BCl2 family that promotes increase in the level of p53 in the cell and activation of
apoptosis; not induced by p53 in all cells p53 as a transcription factor. The p53 level increases
IGF-BP3 The insulin-like growth factor binding protein-
because the half-life of the protein is lengthened and3; blocks signaling of a mitogenic growth factor
possibly because the rate of translational initiation of
While a large number of other genes have been suggested to be p53 mRNA in the cell is enhanced. This increase in p53
regulated by p53 (Ko and Prives, 1996), those listed above all have
levels is proportional to the extent of DNA damage, butbeen shown to contain p53-dependent, cis-acting, DNA-responsive
both the extent of increase and the kinetics of p53 en-elements.
hancement differ for different types of radiation damage.
The cell uses different functions and proteins to recog-
nize different classes of DNA damage (such as breaks
contains a dimer of a dimer with two b sheets and two in the DNA and excision repair of ultraviolet-irradiation
a helices. The two dimers are held together by a large dimers) and different systems of enzymes to repair them.
hydrophobic surface of each helix pair, which then forms It is an attractive idea that the cellular proteins that
a four-helixbundle. This tetramerization domain is linked recognize DNA damage may communicate with p53 and
to thesequence-specific DNA-binding domain by a flexi- activate it. For example, cells in culture defective in the
ble linker of 37 residues (287–323) (Jeffrey et al., 1995). ATM gene (ataxia-telangiectasia) have a delayed and
The C-terminal 26 amino acids form an open (prote- attenuated p53 response to ionizing radiation, sug-
ase-sensitive) domain composed of nine basic amino gesting that the ATM protein, which may recognize dam-
acid residues that bind to DNA and RNA readily with aged DNA and which contains a protein kinase domain,
some sequence or structural preferences (Lee et al., may signal the p53 protein in this fashion (Kastan et al.,
1995). There is considerable evidence demonstrating 1992). While a signal transduction pathway of this type
that the p53 protein derived from several sources re- linking p53 to DNA damage must be postulated, no
quires a structural change to activate it for sequence- clear-cut components of this pathway have been identi-
specific binding to DNA. This non–DNA-binding or latent fied. Because the p53 protein itself can bind to DNA
form of p53 can be regulated by this basic C-terminal ends and excision-repair damage sites or internal dele-
domain. Deletion of thisdomain, phosphorylation atresi- tion loops (Lee et al., 1995), it is possible that both the
due S378 by protein kinase C or residue S392 by casein p53 protein and a damage-detector protein are localized
kinase II, or binding of antibody PAb421 (to residues at the site of DNA damage and repair, where phosphory-
370–378) all activate site-specific DNA binding by the lation or other activating signals can then be processed
central domain (residues 102–292) of this protein (Hupp (Figure 1). This concept has the advantage of requiring
and Lane, 1994). Short (20–39 nucleotides) single two independent checks (the damage-detector protein
strands of DNA interacting with this C-terminal domain and p53) for the presence of DNA damage prior to a
can also activate specific p53 DNA binding, but longer, p53 functional response to such damage.
double strands of DNA inhibit p53 sequence-specific DNA strand breaks in a cell appear to be sufficient
binding through this region of the protein (Jayaraman for activating p53. The introduction of restriction enzyme
and Prives, 1995). The C-terminal domain helps to cata- nucleases into the nucleus of a cell stimulates p53 levels
lyze the reassociation of single-stranded DNA or RNA and activity. Transgenic mice defective in nucleotide
to double strands. It also binds preferentially to DNA excision repair (leaving repair intermediates) have ele-
ends and to internal deletion loops in DNA as generated vated levels of p53 in several tissues. Mice defective in
by replication errors that are then detected and fixed V-D-J receptor recombination (SCID mice) also have an
by mismatch-repair processes. There is some sequence activated p53 owing to the persistence of DNA recombi-
or structural specificity in this binding (Lee et al., 1995). nation intermediates (Guidos et al., 1996).
Clearly, the C-terminal domain either sterically or allo- In addition to DNA damage, hypoxia is able to stimu-
sterically regulates the ability of p53 to bind to specific late p53 levels and activate the p53 protein (Graeber
DNA sequences at its central or core domain. et al., 1996). It has been suggested that this process
represents yet another way that p53 may act as a gate-
The p53 Protein Functions to Integrate Cellular keeper against the formation of cancers. Many tumors
Responses to Stress: Upstream Events begin to replicate and reach a critical size when the
Normally, in a cell, the p53 protein is kept at a low blood supply becomes rate-limiting, requiring angioge-
concentration by its relatively short half-life (about 20 neic factors to sustain growth. The resultant hypoxia
might trigger p53 activity and kill such cells. It has alsomin). The proteases responsible for this are not known,
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Figure 1. The Events in p53 Activation
Figure 2. The p53–Rb PathwayDNA damage (indicated by the break in the double line at the top)
is recognized by a “sensor” molecule that identifies a specific type Experiments discussed in the text permit one to postulate the inter-
relationships among a number of oncogenes (purple circles) andof lesion and possibly by the p53 protein, using its C-terminal do-
main. The sensor modifies p53 (by phosphorylation) when both mol- tumor suppressor genes (green squares) that regulate the G1–S
phase restriction point, its relation to a DNA damage checkpointecules correctly determine that there is damage. A modified p53 is
more stable (enhanced half-life), and a steric or allosteric change mediated by p53, and the choice by p53 whether to initiate a G1
arrest (via p21) or apoptosis. The available evidence suggests anin p53 permits DNA binding to a specific DNA sequence regulating
several downstream genes (p21, MDM2, GADD45, Bax, IGF-BP, and important role for Rb and its two related gene products, p107 and
p130 (along with E2F-4 and -5), in p53-mediated G1–S phase regula-cyclin G). Two modes of signaling for cellular apoptosis are possible:
one requiring transcription and one involving direct signaling with tion. Shown are the p53–MDM2 autoregulatory loop that reverses
this checkpoint control and the gene products that positively orno transcription of downstream genes required.
negatively act on the probability of entering apoptosis.
Responses to the Activation of p53:been reported that the thrombospondin gene is a p53-
Downstream Eventsregulated gene. If that is correct, thrombospondin is an
The downstream events mediated by p53 take place byantiangiogenic factor that could further reduce the blood
two major pathways: cell cycle arrest and apoptosis.supply to these tumors.
Cell Cycle RegulationYet a third signal to activate p53 is sent when ribonu-
The p16–cyclin D1–cdk4–Rb pathway is central to thecleoside triphosphate pools fall below a critical thresh-
regulation of the G1-to-S phase transition and to theold. Clearly, the need to have normal nucleoside triphos-
understanding of human cancers (Figure2). One of thesephate pools to support DNA replication and progression
four genes is altered or mutated in nearly every cancerthrough the cell cycle is monitored and reported to p53,
examined. p16 is a negative regulator of cyclin D1–Cdk4,but the pathway or proteins involved in this remain un-
and the gene is shut off (heavily methylated) in someclear (Linke et al., 1996).
cancer cells or mutated in other cancers. Cyclin D1 isOther signals of cellular distress that use p53 as an
amplified and overexpressed in a number of cancersintegrator of a response have been reported. Recogni-
(about 16% of breast cancers), and cdk4 mutations (no
tion of birth defects in response to teratogenic agents
longer sensitive to p16) and cdk4 gene amplifications
has been singled out as one possible role of p53 (Nicol
have been reported in selected tumors. The retinoblas-
et al., 1995). For example, in the absence of MDM2, the
toma protein (Rb) is the major target of cyclin D1–Cdk4negative regulator of p53, mouse fetuses are aborted for cell cycle regulation and is also present in a mutant
just after implantation, in a p53-dependent fashion form in a number of cancers (such as small-cell lung
(Montes de Oca Luna et al., 1995). Implantation may cancer and osteosarcomas). The Rb protein regulates
trigger stressful signals responded to by p53 and modu- E2F–DP transcription factor complexes (E2F-1, -2, and
lated appropriately by MDM2. Mice nullizygous for the -3, and DP-1, -2, and -3), which in turn regulate a number
p53 gene develop giant cells (polyploid cells) in the tes- of genes (including those encoding cyclin E, cyclin A,
tes, which could result from a lack of surveillance of dihydrofolate reductase, and proliferating cell nuclear
recombination intermediates in spermatocytes. This antigen [PCNA]) required to initiate or propagate the S
could mean that one role of wild-type p53 is to detect phase of the cell cycle. Phosphorylation of Rb by cyclin
abnormal intermediates in recombination and to elimi- D1–Cdk4 releases E2F–DP proteins from the Rb com-
nate such clones during spermiogenesis, as is more plex, relieving repression of these genes or activating
clearly the case with the T cell receptor recombination their transcription. The Rb protein regulates the restric-
intermediates (Guidos et al., 1996). Perhaps related to tion point or start, as a “go–no go” signal for cell cycle
this observation is the finding that the most common progression that is sensitive to the impact of various
tumor that arises in p53 nullizygous mice is a thymic exogenous growth factors (via the regulation of cyclin
D1–Cdk4 and possibly p16).lymphoma (Donehower et al., 1992).
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In response to some forms of DNA damage, p53 is p53 enter S phase and can also amplify segments of
DNA. Gene amplification is thought to arise from nonho-activated and turns on the transcription of one of its
downstream genes, p21 (WAF1, Cip-1) (El-Deiry et al., mologous recombination in a bridge–breakage–fusion
cycle. Although the mechanism by which gene amplifi-1993). p21 binds to a number of cyclin and Cdk com-
plexes: cyclin D1–Cdk4, cyclin E–Cdk2, cyclin A–Cdk2, cation is curtailed and inhibited by p53 remains unclear,
one possibility is that p53 plays a role in monitoringand cyclin A–Cdc2. One molecule of p21 per complex
appears to permit Cdk activity (and may even act as an abnormal recombination intermediates and acts to kill
such cells (Guidos et al., 1996).assembly factor), while two moles of p21 per complex
inhibit kinase activity and block cell cycle progression. More recently, p53 has been implicated in a G2/M
phase checkpoint. When mitotic spindle inhibitors, suchp21 also binds to PCNA (at its C-terminal domain). The
available evidence suggests that p21–PCNA complexes as nocodazole, are added to cells with wild-type p53,
the cells are blocked in G2. In the absence of wild-typeblock the role of PCNA as a DNA polymerase process-
ivity factor in DNA replication, but not its role in DNA p53, these cells will reinitiate DNA synthesis, increasing
the ploidy of the cells (Cross et al., 1995). These datarepair. Thus, p21 can act on cyclin–Cdk complexes and
PCNA to stop DNA replication. Mice deficient in the suggest that p53 may be part of a G2/M checkpoint,
preventing premature entry into another S phase. Inp21 gene (null phenotype) develop normally, and mouse
embryo fibroblasts derived from these mice are partially addition, p53 appears to be an integral part of the pro-
cess that regulates the number of centrosomes in a celldeficient in their ability to arrest cells in G1 in response
to DNA damage (Deng et al., 1995). Based on these (Fukasawa et al., 1996). Mouse embryo fibroblasts from
p532/2 (null) mice produce abnormal numbers of centro-observations, there should be a p21-independent path-
way that contributes to the p53-mediated G1 arrest. The somes (not observed in normal cells in culture at the
same passage level) after a few doublings in cell cultureoverexpression of the product of the GADD45 gene (a
p53-responsive gene) in some cells in culture arrests and initiate spindles with three or four poles (Fukasawa
et al., 1996). This surely contributes to the phenotypecells in G1. Perhaps GADD45, also binding to PCNA,
plays this backup role for p21. By contrast, the removal of p532/2 cells in culture that rapidly become aneuploid
at times when cells with wild-type p53 remain diploidof both p21 alleles from a cancerous cell line in culture
that contained a wild-type p53 allele completely elimi- during their passages. Of note, p53 has been found to
copurify with the centrosomes isolated from some cellsnated the DNA damage–induced G1 arrest in these cells,
indicating that p21 is sufficient to enforce a G1 arrest in culture (Brown et al., 1994). This p53-mediated G2/M
checkpoint may account for the phenotype of genomicin this experimental situation (Polyak et al., 1996). Per-
haps the particular set of mutations in this cancer cell instability that is commonly associated with a p53 mu-
tation.line or the genetic background of these cells plays a
role in the degree to which p21 alone can regulate the A clear example of this phenotype was demonstrated
using the transgenic mouse carrying the MMTV-LTR-G1 checkpoint.
While this model for p53-mediated G1 arrest (Figure Wnt1 transgene that promotes breast cancer. Crossing
this transgene with a p53 2/2 mouse resulted in a more2) predicts that cells with a mutant or faulty Rb protein
should not be blocked in G1 after DNA damage and p53 rapid appearance of breast tumors, and these tumors
were markedly more aneuploid, demonstrating the p53activation, the evidence that supports this rests heavily
on the use of viral oncogenes, which undoubtedly have null genomic instability phenotype in vivo (Donehower
et al., 1995).multiple functions. In these experiments, the SV40 T
antigen, E1A proteins of adenovirus, or E7 of the human Evidence for a third cell cycle checkpoint for p53
comes from an examination of the G0–G1–S phase tran-papilloma viruses are used to block Rb functions and
test for p53-mediated G1 arrest. In the absence of Rb sition. The Gas1 gene is a membrane protein that keeps
cells in G0 arrest and is expressed only at that time.regulation of E2F–DP-1, p53 fails to arrest these cells.
When a simpler protocol is used, such as mouse embryo Gas1 can act to place cells into a G0 arrest only when
wild-type p53 is present in such cells. In this case, how-fibroblasts from Rb2/2 (null) mice that are irradiated in
cell culture, they in fact undergo G1 arrest. One distinc- ever, p53 is not acting as a transcription factor regulating
its downstream genes. The codon 22, 23 mutant of p53,tion between these experiments and those using viral
oncogenes to eliminate Rb function is that such viral which cannot act as a transcription factor, still functions
to transmit Gas1 signals for G0 arrest (Del Sal et al.,oncogene products also alter the other two Rb family
members, p107 and p130, which can certainly play a 1995). This brings up thepossibility that p53 can function
not as a transcription factor but in a second way, per-role in a p53-mediated G1-arrest phenotype. Thus p21
inhibition of cyclin D1–Cdk4 and cyclin E–Cdk2 can still haps by direct protein–protein signaling. This idea is
strongly supported by additional experiments examin-affect the activities of p107 and p130, which regulate
E2F-4 and -5. These interrelationships must be under- ing the role of p53 in apoptosis.
Regulation of Apoptosisstood better if we are to know how p53 regulates G1
arrest. Several experimental protocols have demonstrated that
p53 plays a role in triggering apoptosis under severalCells with wild-type p53 do not undergo gene amplifi-
cation readily (Livingstone et al., 1992). The drug PALA different physiological conditions. Normal thymocytes
will undergo apoptosis in response to DNA damage,(N-phosphonacetyl-L-aspartate), which is used to select
for the amplification of the CAD gene, results in the whereas thymocytes from p53 2/2 mice do not undergo
apoptosis in response to the same stimulus (Lowe etdepletion of pyrimidine triphosphate pools, which in turn
activates p53, resulting in G1 arrest. Cells with mutant al., 1993b). Similarly, in mice that are irradiated, the stem
Review: p53, the Cellular Gatekeeper
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cells of the small and large intestine undergo apoptosis, Clearly, the p53-mediated cell cycle arrest requires p53-
which does not occur in p532/2 mice. However, it is dependent transcription and one or more of its down-
equally clear that not all apoptotic events are p53-medi- stream genes. Does p53-mediated apoptosis require the
ated. For example, immature thymocytes from p532/2 transcriptional activity of p53? Furthermore, how does
mice die of apoptosis when exposed to glucocorticoids p53 sense the presence of an activated oncogene in a
or compounds that trigger T cell receptor pathways cell (or a pathway activated by an oncogene)? A number
(Lowe et al., 1993b). of experiments addressing the first question, concerning
Physiological signals or activation of a specific signal the need for p53-mediated transcription to induce apop-
transduction pathway can block p53-mediated apop- tosis, have concluded that both a p53-mediated tran-
tosis. Myeloid leukemic cells or murine erythroleukemic scriptional activity and a p53 activity not requiring tran-
cells will undergo apoptosis when p53 is overexpressed scription can play a role in apoptosis, and the choice
and activated (Yonish-Rouach et al., 1991). Treatment depends on the cell type or experimental situation. In
of the myeloid cells with interleukin-6 or the erythroid several cell types, p53-mediated apoptosis initiated by
cells with erythopoeitin blocks the p53-mediated apop- DNA damage occurs in the presence of actinomycin D
tic pathway (Yonish-Rouach et al., 1991; Johnson et al., or cycloheximide, which block RNA or protein synthesis
1993). In this case, communication between p53 and a (Caelles et al., 1994). Similarly, a temperature-sensitive
signal transduction pathway results in the reversal of p53 in a cell with an activated myc induces apoptosis
p53-mediated apoptosis. Thus, it is possible that p53 normally at 328C in the presence of cycloheximide
may play a role in monitoring developmental factor de- (Wagner et al., 1994). Clearly, transcriptional activation
pendence in the hematopoietic system. or the translation of p53- regulated gene products are
p53 can also initiate apoptosis in response to the not required in these cases for apoptosis. Similarly, the
expression of a viral or cellular oncogene or the absence introduction of a p53 cDNA fragment that encodes
of a critical tumor suppressor gene product (Rb). The amino acid residues 1–214 into HeLa cells induces
expression of the adenovirus E1A protein in rat embryo apoptosis (Haupt et al., 1995). p53 (residues 1–214) fails
fibroblasts stabilizes and activates p53. The resultant to bind to DNA or act as a transcription factor. Similarly,
cells die of apoptosis (Debbas and White, 1993). The p53 with mutations in the transactivating domain (resi-
adenoviruses normally express the E1B-55Kd protein, dues 22 and 23) that is unable to activate transcription
which binds to p53 and blocks its transcription factor still induces apoptosis in HeLa cells. By contrast, the
activity, and the E1B-19Kd protein, which acts like BCl2 expression of E1A in baby rat kidney cells or mouse cells
to block apoptosis downstream of p53 activation. The failed to induce apoptosis when p53 contains mutations
human papilloma virus E7 protein acts like E1A and that alter p53-specific DNA binding or transcriptional
induces p53-mediated apoptosis. In response, the hu- activation (Sabbatini et al., 1995). Indeed, the mutantp53
man papilloma virus genome encodes the E6 oncogene that produces amino acid residues 1–214 and induces
product to bind to p53 and degrade it. Transgenic mice apoptosis in HeLa cells fails to induce apoptosis in an-
expressing E7 in the retina photoreceptor cells show other cell type, a human lung carcinoma, cell line H1299
extensive apoptosis. The expression of E7 in these same (Haupt et al., 1995). Thus, it appears that p53 may use
cells but in a p532/2 mouse results in a reduced fre- transcriptional activation or directprotein signaling (pro-
quency of apoptosis and an increased frequency of de- tein–protein interactions or some other activity) or both
velopment of retinal tumors (Howes et al., 1994). The to initiate apoptosis.
E1A and E7 proteins bind to theRb protein and inactivate Two of the genes that are regulated by p53 (in at least
its ability to regulate E2F–DP-1 activity. Such an unregu- some cell types) could influence the decision to commit
lated E2F-1 activity in concert with activated p53 results
to an apoptotic pathway: bax and IGF-BP3 (Miyashita
inapoptosis. Cells overexpressingE2F-1 and a tempera-
and Reed, 1995; Buckbinder et al., 1995). It is clear that
ture-sensitive p53 undergo apoptosis at 328C but not
overexpression of BCl2 (or the adenovirus E1B-19Kd
37–398C, where p53 is inactive (Wu and Levine, 1994).
protein) can block p53-mediated apoptosis. Bax bindsOther oncogenes also trigger p53-mediated apoptosis.
to BCl2 and antagonizes its ability to block apoptosis,Cells overexpressing myc and a temperature-sensitive
so a p53-dependent bax synthesis could tip the scalesp53 have a temperature-sensitive apoptotic response
toward apoptosis. The mechanism of action of the BCl2–(Wagner et al., 1994).
Bax family of gene products remains unclear and isThus, a number of factors affect the decision of a cell
central to understanding this important aspect of theto enter a p53-mediated cell cycle arrest or apoptotic
development of cancer cells. A second p53-regulatedpathway. Under conditions in which the DNA is dam-
gene product that could affect growth regulation is theaged, survival factors for the cells are limiting, or an
insulin-like growth factor–binding protein-3 (IGF-BP3)activated oncogene is forcing the cell into a replicative
(Buckbinder et al., 1995). IGF-BP3 blocks the IGF mitoticcycle (E1A, E7, E2F-1, or myc), p53-mediated apoptosis
signaling pathway by binding to IGF and preventing itsprevails. In this way, cells with unstable genomes (due
interaction with its receptor. Thus, the blocking of IGFto DNA damage) or cells in an abnormal environment
activity could enhance apoptosis or lower the mitogenic(i.e., located in a place with limiting survival factors) with
response of cells. It has been reported that the fas/apo1activated oncogenes that commit them to enter the cell
gene may also be regulated by p53. p53 responsivecycle are eliminated in a p53-dependent apoptotic
elements have not yet been demonstrated in the fas/event. This is most likely the reason why so many can-
apo1 gene and so proof that it is truly a p53-regulatedcerous cells select against wild-type p53 function.
These observations bring up a number of questions. gene remains to be provided.
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by two genes, xeroderma pigmentosum complementa-Table 2. Proteins That Have Functional Interactions with p53
tion groups D and B (XP-B and XP-D). Other subunits
Viral proteins
of TFIIH are the cyclin H–Cdk7–p36 proteins involved inSV40 T antigen Blocks p53 DNA binding domain
DNA repair (the cyclin activating kinase) and transcrip-AdE1B 55 kDa Blocks p53 transcriptional activation
tion initiation by RNA polymerase II. p53 binds to thesedomain
Human papilloma Promotes the degradation of p53 two helicases in vitro (XP-B and XP-D gene products) as
virus E6 well as to a third helicase, which isdefective in Cockayne
Oncogene products syndrome. This helicase, termed CsB, is involved in yet
MDM2 Blocks p53 transcriptional activation
another DNA repair pathway. While it has been difficultdomain
to prove that those protein–protein interactions ob-c-Abl p53-mediated cell cycle arrest
served in vitro have a physiologically meaningful coun-Transcriptional factors
TATA-binding protein Binds amino and carboxyl termini of terpart in vivo, it was recently shown that cells deficient
p53 for the XP-B or XP-D helicases fail to undergo apoptosis
TAF70, TAF31 Binds to amino-terminal domain of mediated by p53. These observations leave open the
p53
possibility that p53 itself plays a role in modulating nu-TFIIH
clear excision repair. For example, the binding of p53ERCC2, XPD Helicase modulated by wild-type p53,
to XP-B and XP-D proteins in vitro blocks their helicasenot mutant p53
ERCC3, XPB Helicase modulated by wild-type p53, activity, while mutant p53, R273H, binds to these pro-
not mutant p53 teins but fails to inhibit their helicase activity in a manner
WT1 (Wilms tumor-1) Alters p53 activities comparable to the wild-type p53 protein (Wang et al.,
A detailed list of references for these observations and additional 1995).
proteins thought to interact with p53 is presented by Ko and Prives, The Wilms tumor suppressor gene product, WT1, has
1996. beenshown toassociate with p53 when both areoverex-
pressed in the same cell (Maheswaran et al., 1995).
Coexpression of p53 and WT1 results in higher steady-
p53–Protein Interactions state levels of p53, an increased level of p53 binding
It has been shown that p53 directly binds to and acts to sequence-specific DNA targets, and an enhanced
on several cellular proteins (Table 2). Among these, the transcriptional activity. In U20S cells in culture, the ex-
c-Abl protein has several noteworthy properties. First, pression of WT1 blocks a p53-mediated apoptosis
nuclear c-Abl is activated for its kinase activity after which is triggered by ultraviolet irradiation. Thus WT1,
DNA damage, and c-Abl binds to p53 and enhances its at least at abnormally high concentrations, can have
transcriptional activity. The overexpression of c-Abl in specific effects on p53 activity and physiological ac-
normal cells blocks cell cycle progression, and this is tions.
dependent ona wild-type p53 activity (Goga et al., 1995).
Thus, there is a growing linkage between Abl and p53 A Role for p53 in Senescence
in a common pathway. c-Abl, but not the product of Normal mouse or human cells recently obtained from
v-abl activated as an oncogene, contains an SH3 (Src their host undergo a limited number of divisions in cul-
homology domain 3) binding domain. The human p53 ture. The murine cells undergo senescence more rapidly,
protein contains five copies of the amino acid motif after only a few divisions, but it is common that some
proline-X-X-proline (where X is any amino acid) localized cells escape and can form permanent cell lines in cul-
between residues 61–94, and this motif has been shown ture. The human cells, on the other hand, slow their
to bind to SH3 domains. Deletion of this proline-rich growth rate and stop dividing with little or no evidence
region of the p53 protein permits normal p53-mediated of a cell that can form a permanent cell line. SV40 large
transcriptional activation but significantly reduces the T antigen, which inactivates p53 and Rb and alters p300
ability of this p53 mutant protein to mediate apoptosis and the related CREB-binding protein activities, can ex-
or cell cycle arrest (Walker and Levine, 1996). The possi- tend the life span of human cells providing additional
bility of a regulated interaction between p53 and SH3 generations, but does not by itself (without additional
domain–containing proteins is one way to communicate events or mutations) produce a permanent cell line in
with signal transduction pathways and sense oncogene culture. Rather, T antigen–expressing human cells in late
activities. Recently, a Li-Fraumeni syndromefamily, with passage enter a crises phase and fail to reproduce.
three late-onset breast cancers, has been described Only rare cells emerge expressing T antigen and form
with a mutation in the proline at codon 82, disrupting permanent cell lines. These cells are dependent on T
one of the proline-X-X-proline repeats. In two of the antigen expression for their ability to divide.
three tumors, there was a partial p53 reduction to homo- p53-deficient murine cells from a p53 nullizygous
zygosity in recurrent tumors, eliminating the wild-type mouse readily escape senescence and produce aneu-
allele. This mutation, however, did not appear to be ploid immortalized cell lines. This is most likely due to
the major cause of the neoplastic disease, but rather the loss of p53-mediated control over centrosome dupli-
confered only a portion of the phenotype onthe progres- cation (Fukasawa et al., 1996) and the G2/M checkpoint
sion of the breast cancer (Sun et al., 1996). (Cross et al., 1995) preventing reinitiation of S-phase
The p53 protein has also been shown to bind to an prior to mitosis or the next G1 phase. In addition, it has
RNA polymerase II basal transcription factor, TFIIH become clear that p53 responds to signals provided by
(Wang et al., 1995). TFIIH consists of two helicases, normal cells undergoing progressive passages in cul-
ture. p53 activity increases in late-passage cells, andERCC2 and ERCC3, which are the proteins encoded for
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p21 levels increase as well, slowing or stopping the the selection for p53 mutations surely depends on a
division rate of the culture. The addition of a transdomi- complex set of variables. Because p53 is induced and
nant-acting p53 mutant to such cells provides a signifi- activated by hypoxia, the need for angiogenic factors
cant enhancement in the lifespan of those cells (Bond (or the loss of antiangiogenic factors) is balanced with
et al., 1995). These cells will still undergo senescence the elimination, via mutation, of p53. A rich blood supply
at a later passage level, showing that further oncogenic early in tumor development may leave p53 mutations to
events are required for immortalization. For example, be selected at a later time.
the addition of cDNA clones encoding the c-myc or raf Clearly, the genetic background of the host has a
oncogenes readily immortalize p53-deficient cells at a significant impact on the tumor type initiated by p53
higher rate than cells containing wild-type p53. mutations. In 129 mice, which develop testicular terato-
carcinomas at a 1–3% frequency, a null genotype
The Role of p53 in Tumor Formation (p532/2) increases this frequency to 25–40% of male
p53 mutations are found in 50–55% of all human cancers mice. 129XC57Bl/6 hybrid mice rarely, if ever, develop
(Hollstein et al., 1994). These mutations strongly select these tumors (Donehower et al., 1992). Thus, the ab-
for p53 proteins that fail to bind to DNA in a sequence- sence of p53 can enhance an inherited predisposition
specific fashion. While the cell cycle arrest functions of to a particular cancer. Mice that are nullizygous for p53
p53 require p53 transcriptional activity, at least some and heterozygous for Rb (Rb1/2) are susceptible to a
of the apoptotic activities of p53 do not require p53- much wider range of tumors, with different cell and tis-
dependent gene products. This could mean that tran- sue types involved, than are mice with either mutation
scription of selected p53 target genes is critical to its alone (Williams et al., 1994). Therefore, these two tumor
tumor suppressor function (i.e., some forms of apop- suppressor genes, p53 and Rb, can cooperate to pro-
tosis are not critical) or that the p53 direct signaling duce new phenotypes. As indicated previously, Wnt1-
pathway, in the absence of transcription, requires p53 induced breast tumors (oncogene–transgene) appear
to bind to DNA in a sequence-specific fashion. Clearly earlier and have abnormal ploidy when they arise in
the enhancer elements recognized by p53 in the DNA p532/2 mice (Donehower et al., 1995). In addition, mice
are not all equally regulated by it. Some p53 mutant that are heterozygous for p53 (p531/2) produce a differ-
proteins can activate a p53 responsive sequence in the ent spectrum of tumors than p532/2 mice (Donehower
p21 gene but not the bax gene (Friedlander et al., 1996). et al., 1995). Clearly, cancer is a disease in which allelic
This could indicate that bax transcriptional activation differences and the genetic background of the host af-
(apoptosis) is selected against more frequently than is fect the age of onset, incidence, and tumor type that is
that of p21 and bax together (G1 arrest). In addition detected first in life.
to p53 mutations, some tumors inactivate p53 by the As might be predicted from the known functions of
amplification of the MDM2 gene (about one third of all p53, mice that are nullizygous for p53 aremore suscepti-
sarcomas) (Oliner et al., 1992) or by the localization of ble to g-irradiation or to carcinogens for inducing tumors
p53 in the cell cytoplasm (a small number of breast in animals. However, there is no evidence for an en-
tumors and neuroblastomas). In other cancers, p53 mu- hanced rate of point mutations in p532/2 mice treated
tations are never selected (teratocarcinomas). In this with these agents. Perhaps p53 plays a more central
case, the wild-type p53 protein in the cancerous stem role in the surveillance of gene amplifications, abnormal
cells is not a functional transcription factor, and that is recombination processes, and the control over ploidy.
presumably the reason for the absence of selection of
Certainly, the observations that the p53 nullizygous mice
p53 mutations (Lutzker and Levine, 1996).
develop thymic lymphomas (Donehower et al., 1992)
Humans who are heterozygous for the wild-type allele
and that p53 plays a critical role in the surveillance of
of p53 develop cancer with a very high frequency
T cell recombination intermediates (Guidos et al., 1996)(greater than 90–95%) and often at an early age. The
supports these ideas.cell and tissue distributions of these cancers (sarcomas,
It is equally clear that p53 acts to reduce the incidencebreast, and adrenal carcinomas) is not random, and it
of cancers by mediating apoptosis in cellswith activatedis not clear what this means either for p53 function or
oncogenes. Transgenic mice expressing the SV40 largethe additional mutations that are required to develop
T antigen develop choroid plexus papillomas during thecancer in a p53 heterozygous cell. There are some indi-
first 3 months of life. The tumor growth is slowed consid-cations that p53 heterozygous cells show dosage ef-
erably by p53-mediated apoptosis when a T antigenfects in chemically induced mouse skin tumors (Kemp
mutant is used that cannot inactivate p53 functions inet al., 1993), suggesting that the level of p53 in a cell
these cells. When this mutant is expressed in p532/2influences the phenotype. The timing of p53 somatic
mice, the rapid tumor growth resumes with lessmutations in human cancers contributing to malignant
apoptosis (Symonds et al., 1994). Clearly, then, p53-tumors apparently depends on the tumor type. Most
mediated apoptosis is an important part of the tumorcolorectal tumors arise via a series of genetic changes,
suppressor phenotype and subsequent selection forfirst in the APC gene and then in the ras gene, followed
mutant p53 genes in cancers.by mutations in the DCC gene and finally in the p53
gene. While the APC mutation may have to occur prior
to the others, the order is not rigidly fixed, but it is
p53 and Cancer Treatment and Prognosisthe most commonly observed one. In skin cancers, by
The treatment of neoplasia using radiation and chemo-contrast, a p53 mutation appears to occur early in pre-
malignant lesions (Ziegler et al., 1994). The timing of therapy results in extensive DNA damage and signaling
Cell
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human diploid cells from senescence without inhibiting the inductionto p53 in those cells. In some selected cases, it is be-
of SKI1/WAF1. Cancer Res. 55, 2404–2409.coming clear that p53-dependent apoptosis can modu-
Brown, C.R., Doxsey, S.J., White, E., and Welch, W.J. (1994). Bothlate the toxic effects of anticancer agents. Cells in cul-
viral (adenovirus E1B) and cellular (hsp 70, p53) components interactture activated by the expression of the adenovirus
with centrosomes. J. Cell. Physiol. 160, 47–60.
oncogene E1A undergo a p53-dependent programmed
Buckbinder, L., Talbott, R., Valesco-Miguel, S., Takenaka, I., Faha,cell death in response to ionizing radiation or treatment
B., Seizinger, B.R., and Kley, N. (1995). Induction of the growth
with 5-fluorouracil, etoposide, or adriamycin (Lowe et inhibitor IGF-binding protein 3 by p53. Nature 377, 646–649.
al., 1993a). A similar situation exists with testicular tera- Caelles, C., Heimberg, A., and Karin, M. (1994). p53-dependent
tocarcinomas. All human and mouse testicular terato- apoptosis in the absence of p53-target genes. Nature 370, 220–223.
carcinomas examined to date contain wild-type p53 Cho, Y., Gorina, S., Jeffrey, P.D., and Pavletich, N.P. (1994). Crystal
genes (Lutzker and Levine, 1996). This is one of the structure of a p53 tumor suppressor-DNA complex: understanding
human tumors that respond very well (90–95% cures) tumorigenic mutations. Science 265, 346–355.
to chemotherapy with cisplatin. In cell culture the stem Cross, S.M., Sanchez, C.A., Morgan, C.A., Schimke, M.K., Ramel, S.,
Idzerda, R.L., Rasking, W.H., and Reid, B.J. (1995). A p53-dependentcells of this tumor undergo a p53-dependent apoptosis
mouse spindle checkpoint. Science 267, 1353–1356.in response to etoposide (Lutzker and Levine, 1996). A
Debbas, M., and White, E. (1993). Wild-type p53 mediates apoptosissimilar situation has been noted with childhood acute
by E1A which is inhibited by E1B. Genes Dev. 7, 546–554.lymphoblastic leukemias, which most often have wild-
Del Sal, G.D., Ruaro, E.M., Utrera, R., Cole, C.N., Levine, A.J., andtype p53 and respond well to chemotherapeutic inter-
Schneider, C. (1995). Gas1-induced growth suppression requires avention (Lowe et al., 1993a). When these tumors relapse,
transactivation-independent p53 function. Mol. Cell. Biol. 15, 7152–ineffectiveness of therapy correlates well with the acqui-
7160.
sition of p53 mutations. Other tumors that frequently
Deng, C., Zhang, P., Harper, J.W., Elledge, S.J., and Leder, P. (1995).contain p53 mutations (melanoma, lung cancers, colo- Mice lacking p21CIP1/WAF1 undergo normal development, but are de-
rectal tumors, and bladder and prostate cancers) often fective in G1 checkpoint control. Cell 82, 675–684.
respond poorly to radiation or chemotherapy. In breast Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A.K., Moore, M.,
cancers, p53 mutations were well correlated with de Finlay, C., and Levine, A.J. (1993). p53 gain of function mutations.
novo resistance to doxorubicin treatment (Aas et al., Nature Genet. 4, 42–46.
1996). Similar findings have been reported for chemo- Donehower, L.A., Godley, L.A., Aldaz, C.M., Pyle, R., Shi, Y.-P.,
Pinkel, D., Gray, J., Bradley, A., Demina, D., and Varmus, H.E. (1995).therapy with small-cell lung cancers responding to cis-
Deficiency of p53 accelerates mamary tumorigenesis in Wnt-1platin or in mice in which anthracyclines were used to
transgenic mice and promotes chromosomal instability. Genes Dev.treat sarcomas. It is not surprising therefore that in some
9, 882–895.cases p53 mutations have been reported to result in
Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Mont-shorter disease-free survival and lower total survival of
gomery, C.A., Jr., Butel, J.S., and Bradley, A. (1992). Mice deficient
patients (Aas et al., 1996). for p53 are developmentally normal but susceptible to spontaneous
This good correlation between p53 functional status tumours. Nature (Lond.) 356, 215–221.
and treatment response or prognosis is not always the El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R.,
case. It is clear that cancer cells suffer a large number Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vogelstein, B.
of genetic changes, some of which contribute to the (1993). WAF1, a potential mediator of p53 tumor suppression. Cell
75, 817–825.overall phenotype and others that do not. The changes
Friedlander, P., Haupt, Y., Prives, C., and Oren, M. (1996). A mutantin the cellular environment during treatment, the possi-
p53 that discriminates between p53-responsive genes cannot in-bility of an altered mutation rate, and the large number
duce apoptosis. Mol. Cell. Biol. 16, 4961–4971.of physiological variables all confound clear-cut correla-
Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., and Vande Woude,tions between the status of a single gene and a re-
G. F. (1996). Abnormal centrosome amplification in the absence ofsponse. We must begin to understand several variables
p53. Science 271, 1744–1747.
at a time if we are to accurately make predictions of
Goga, A., Liu, X., Hambuch, T.M., Senechal, K., Major, E., Berk,treatment responses and outcomes of diseases. At least
A.J., Witte, O.N., and Sawyers, C.L. (1995). p53-dependent growth
we now know some of the variables. suppression by the c-Abl nuclear tyrosine kinase. Oncogene 11,
791–799.
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